All In Biotech

Free tool

FAERS Monitor: Elimite

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019855 or its brand name (Elimite, Permethrin). Reports on generic versions are filed under their own applications.

Reports

1,358

Serious

690

51% of reports

Hospitalization

221

Death reported

58

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective209
  • off label use112
  • pruritus103
  • pain90
  • anxiety69
  • chronic kidney disease67
  • rash61
  • nausea60
  • headache58
  • diarrhoea55
  • dry skin54
  • fatigue49
  • emotional distress47
  • inappropriate schedule of drug administration47
  • renal failure45

Reports by year received

View as table
YearReports
200411
20059
20067
20074
20085
200917
201028
201121
201229
201324
201433
201540
201684
201792
2018137
2019155
2020141
2021134
202280
202374
202498
202598
202637

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,801 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal6713.710.8776
inappropriate schedule of drug administrationSignal4710.27.7384
dry skinSignal546.34.8235
emotional distressSignal476.04.5193
renal failureSignal455.23.9151
pruritusSignal1034.23.4248
anxietySignal693.83.0139
drug ineffectiveSignal2092.52.2191
painSignal902.31.965
rashSignal612.21.738
off label use1122.01.756
headache581.41.17
diarrhoea551.31.04
nausea601.20.91
fatigue491.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.